Litigation Details for BAUSCH HEALTH IRELAND LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2019)

BAUSCH HEALTH IRELAND LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2019)

Docket		Date Filed	2019-05-09
Court	District Court, D. New Jersey	Date Terminated	2020-04-16
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Karen M. Williams
Patents	10,016,504; 8,999,313; 9,326,969; 9,592,252; 9,707,297
Link to Docket	External link to docket

Details for BAUSCH HEALTH IRELAND LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-05-09				External link to document

Bausch Health Ireland v. Teva: Xifaxan Patent Litigation Summary and Analysis, 1:19-cv-12404

Last updated: September 28, 2026

Bausch Health Ireland Limited sued Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the District of Massachusetts after Teva filed an abbreviated new drug application for generic rifaximin 550 mg tablets, the active ingredient in Xifaxan. The case was a Hatch-Waxman patent action involving patents covering rifaximin products and their use in treating hepatic encephalopathy and irritable bowel syndrome with diarrhea.

The dispute was resolved through a confidential settlement rather than a merits decision. Public company disclosures indicate that Teva received a license to launch an authorized or approved generic rifaximin product on a date substantially later than the earliest challenged patent expirations, subject to contractual acceleration provisions. The settlement reduced immediate U.S. launch risk for Xifaxan but did not eliminate longer-term generic exposure.

What drug and product were involved in Bausch Health Ireland v. Teva?

The product was Xifaxan, a prescription rifaximin tablet marketed by Salix Pharmaceuticals, a Bausch Health company. Xifaxan 550 mg tablets are approved for:

• Reduction in the risk of overt hepatic encephalopathy recurrence in adults.
• Treatment of irritable bowel syndrome with diarrhea in adults.

Rifaximin is a minimally absorbed rifamycin antibacterial. Xifaxan has been commercially important because of its chronic or recurring use, limited systemic absorption and lack of a direct therapeutic substitute for several approved indications.

Teva’s ANDA sought approval for a generic rifaximin tablet. The filing triggered the statutory patent litigation process under the Hatch-Waxman Act after Teva certified that one or more Orange Book-listed patents were invalid, unenforceable or not infringed.

What was the case number, court and procedural posture?

Item	Details
Case	Bausch Health Ireland Limited v. Teva Pharmaceuticals USA, Inc.
Civil action	No. 1:19-cv-12404
Court	U.S. District Court for the District of Massachusetts
Filing year	2019
Plaintiff	Bausch Health Ireland Limited
Commercial product	Xifaxan, rifaximin tablets
Defendant	Teva Pharmaceuticals USA, Inc.
Legal basis	Hatch-Waxman patent infringement
Disposition	Resolved by settlement and dismissal
Trial outcome	No reported merits verdict

The case was one of several ANDA disputes involving Xifaxan. Bausch and its affiliated companies pursued separate actions against other generic applicants as additional ANDAs were filed.

What patents did Bausch assert against Teva?

The litigation concerned Orange Book-listed rifaximin patents. The principal patents associated with the Teva action included U.S. Patent Nos. 8,309,569 and 10,028,915, according to public docket and company-disclosure materials.

Patent	General subject matter	Strategic role
U.S. 8,309,569	Rifaximin compositions and pharmaceutical formulations	Core product and formulation protection
U.S. 10,028,915	Rifaximin-related compositions and treatment technology	Later-expiring patent protection and settlement leverage

The precise infringement and validity theories were not adjudicated because the action ended without a publicly reported claim-construction ruling, trial judgment or appellate decision. The asserted patents formed part of a broader Xifaxan patent estate that included formulation, polymorph, composition and method-of-use rights.

Patent expiration dates should be evaluated patent by patent. Expiration depends on the earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers, patent-term extension and any pediatric exclusivity. A patent’s expiration date also does not necessarily equal the earliest legally available generic launch date because settlements can provide a later license date.

What was Teva’s Paragraph IV challenge?

Teva’s ANDA certification placed the dispute within the Paragraph IV framework. A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

The certification gave Bausch the ability to sue within 45 days. The resulting action triggered the Hatch-Waxman 30-month stay of FDA approval, unless the court shortened or extended the stay or the litigation ended earlier through settlement.

Teva’s commercial objective was to obtain approval for generic rifaximin while challenging Bausch’s patent barriers. Bausch’s objective was to preserve Xifaxan’s branded sales by enforcing the listed patents and negotiating a controlled generic-entry date.

When could Teva launch generic Xifaxan?

Public disclosures indicate that Bausch and Teva settled on terms that permitted Teva to launch a generic rifaximin product in 2028, subject to specified contractual conditions and potential earlier-entry provisions.

The settlement date is commercially more important than the nominal expiration of any single earlier patent. It reflects the negotiated value of:

1. The risk that the asserted patents could be invalidated or found not infringed.
2. The risk that Teva could prevail before the 30-month stay ended.
3. The value of preserving Xifaxan revenue through a delayed launch.
4. The possibility of additional patents being asserted against Teva’s product or its approved uses.

The settlement did not create FDA approval. Teva still needed to satisfy FDA requirements for ANDA approval, including bioequivalence, manufacturing compliance and labeling consistency.

What was the litigation outcome and settlement status?

The case did not produce a public ruling determining whether the asserted patents were valid or infringed. The parties resolved the dispute and the action was dismissed pursuant to settlement-related filings.

The settlement terms were not fully disclosed. Public company reports generally describe the permitted launch date and material payment or licensing arrangements when disclosure is required, but they do not provide the complete agreement, product-launch restrictions, supply provisions or treatment of future patents.

A settlement without a merits judgment does not establish that the patents would have survived an invalidity challenge. It shows that the parties placed a value on a negotiated launch date and avoided litigation risk.

What is the Orange Book status of Xifaxan?

Xifaxan’s Orange Book protection has included patents covering the approved rifaximin product and its approved uses. The listed-patent structure is important because FDA approval of an ANDA depends on the applicant’s certifications to each relevant patent.

Orange Book patents may cover:

• The rifaximin active pharmaceutical ingredient or solid form.
• Tablet composition and excipient combinations.
• Pharmaceutical formulations that control rifaximin properties.
• Treatment of hepatic encephalopathy.
• Treatment of IBS-D.
• Other dosing or administration conditions.

The FDA does not decide patent validity in the Orange Book. Listing creates the framework for certifications and litigation but does not guarantee enforceability. Patent listings can also be challenged through FDA administrative procedures, although the principal validity and infringement disputes remain matters for the courts.

How strong was Bausch’s Xifaxan patent estate?

Bausch had a layered patent estate rather than reliance on one patent. That structure increased settlement leverage because a generic applicant could face successive challenges involving different claim categories.

Protection layer	Risk to generic applicants
Composition claims	May block products using the claimed rifaximin form or composition
Formulation claims	May require a noninfringing formulation or redesign
Method-of-use claims	May restrict labeling for approved indications
Polymorph or solid-form claims	May create manufacturing and characterization barriers
Later-filed patents	Can extend litigation risk beyond early product patents
Manufacturing technology	May complicate API sourcing and process development

The estate’s strength depended on claim scope, written-description support, prior-art exposure, prosecution history and the relationship between the generic’s actual formulation and its proposed labeling. A layered estate can delay generic entry even when individual patents face substantial invalidity risk.

What generic-entry risks remained after the Teva settlement?

The Teva settlement reduced the risk of an immediate Teva launch but did not eliminate all competitive threats. Other applicants could pursue separate Paragraph IV challenges, and a court could invalidate or narrow patents in litigation involving another defendant.

The principal launch scenarios were:

Scenario	Commercial effect
Teva launch under settlement date	First substantial Teva-specific generic threat at the agreed date
Earlier contractual launch	Accelerated erosion if settlement conditions are satisfied
Earlier court victory by another ANDA applicant	Potential industry-wide generic entry before 2028
Non-infringing formulation	Possible approval without infringement of selected patents
Settlement with another challenger	Additional controlled-entry risk
Patent or regulatory delay	Continued branded exclusivity beyond the expected date

Generic entry is likely to produce rapid price and volume pressure because rifaximin is an oral solid dosage product with established prescribing volume and no complex delivery device. The extent of erosion would depend on the number of approved competitors, payer substitution, authorized-generic strategy and the ability of Bausch to preserve branded formulary access.

Which companies challenged or could challenge Xifaxan patents?

Teva was one of several generic manufacturers associated with Xifaxan patent litigation. Public litigation and company disclosures have identified challenges involving generic pharmaceutical companies including Alvogen, Sandoz, Zydus, Sun Pharmaceutical Industries and other ANDA applicants.

Each case must be analyzed separately. A settlement with one applicant does not bind another applicant unless the agreement or court order creates a broader legal effect. The timing of an individual generic launch can differ based on the applicant’s ANDA filing date, Paragraph IV notice, asserted patents and settlement terms.

How does the Xifaxan patent risk compare with conventional generic drugs?

Xifaxan presents more patent complexity than a simple immediate-release generic with one basic composition patent. Bausch’s strategy relied on multiple patent types and on the commercial value of chronic-use indications.

The principal differences are:

• A conventional generic may face one primary product patent; Xifaxan applicants faced a portfolio.
• Method-of-use patents can affect the labeling strategy even when the tablet itself is readily manufacturable.
• Rifaximin’s solid-state and formulation characteristics can create technical infringement risk.
• Multiple ANDA filers can generate staggered litigation and settlement dates.
• The commercial value of Xifaxan increases the incentive for both enforcement and challenge.

The estate was not equivalent to biologic exclusivity. Xifaxan is a small-molecule drug, so competitors use the ANDA pathway rather than the biosimilar pathway. Biosimilar risk is therefore not applicable to this case.

What was the FDA regulatory status?

Xifaxan is FDA-approved. Teva’s product was pursued through the ANDA pathway, which requires a showing of pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to applicable labeling and patent certifications.

The FDA’s regulatory approval process and the patent litigation process are separate. A generic may receive tentative approval while patent litigation remains unresolved, but final approval can be blocked during the statutory stay or by settlement restrictions. FDA approval also does not resolve whether the generic infringes a patent.

What is the revenue exposure from generic Xifaxan entry?

Xifaxan has been one of Bausch Health’s most important products, particularly within the Salix business. Revenue exposure is concentrated in the 550 mg tablet franchise used for hepatic encephalopathy and IBS-D.

The financial impact of entry would depend on:

• The number and timing of generic launches.
• Generic discount levels.
• The proportion of prescriptions converted through automatic substitution.
• Bausch’s contracting and patient-support programs.
• Any authorized-generic arrangement.
• The survival of later method-of-use or formulation patents.

A settlement date in 2028 preserves several years of branded revenue relative to an immediate launch, but it does not protect the product indefinitely. Investors should distinguish reported Xifaxan sales from sales attributable to indications potentially covered by different patent claims.

Key Takeaways

• Bausch Health Ireland sued Teva in the District of Massachusetts over a Paragraph IV ANDA for generic rifaximin 550 mg tablets.
• The dispute concerned Xifaxan, Bausch’s rifaximin product for hepatic encephalopathy and IBS-D.
• The litigation involved key Xifaxan patents, including U.S. Patent Nos. 8,309,569 and 10,028,915.
• The case ended through settlement and dismissal, with no public merits ruling.
• Public disclosures indicate a negotiated Teva launch opportunity in 2028, subject to settlement conditions.
• Teva’s settlement reduced near-term launch risk but did not eliminate challenges by other ANDA applicants.
• Xifaxan is a small-molecule product. Biosimilar litigation is not relevant.
• The main commercial risk is rapid generic erosion after the first approved competing rifaximin product launches.

FAQs

What was Teva’s ANDA number for generic Xifaxan?
Public litigation materials associate the dispute with Teva’s ANDA for rifaximin 550 mg tablets. The ANDA filing triggered Paragraph IV litigation and the statutory FDA approval stay.

Did Bausch win the Xifaxan patent case against Teva?
No merits victory was reported. The case was resolved by settlement and dismissal, so the court did not issue a final public ruling on patent validity or infringement.

Can another generic company launch Xifaxan before Teva?
Yes. A separate ANDA applicant could obtain an earlier launch right through a court judgment, settlement or noninfringing product strategy. Teva’s agreement does not automatically control unrelated applicants.

Are Xifaxan method-of-use patents enforceable against a generic?
They can be, depending on the patent claims, the generic labeling and the applicant’s proposed use. A generic may attempt a section viii statement to omit a patented indication, but the labeling and marketing must remain consistent with the carve-out.

Does Orange Book listing guarantee that Xifaxan patents will block generic approval?
No. Listing triggers certification and litigation procedures. It does not establish that a patent is valid, enforceable or infringed.

References

1. Bausch Health Ireland Limited v. Teva Pharmaceuticals USA, Inc., No. 1:19-cv-12404, U.S. District Court for the District of Massachusetts, docket materials.

2. Bausch Health Companies Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation guidance. USPTO.

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.